Cost-Effectiveness of Linezolid versus Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Confirmed Nosocomial Pneumonia in China.

Tan, Seng C; Wang, Xue; Wu, Benquan; Kang, Hongjun; Li, Qiang; Chen, Yixi; Chen, Chieh-I; Hajek, Petr; Patel, Dipen A; Gao, Xin

Tan, Seng C; Wang, Xue; Wu, Benquan; Kang, Hongjun; Li, Qiang; Chen, Yixi; Chen, Chieh-I; Hajek, Petr; Patel, Dipen A; Gao, Xin.

Afiliação

Tan SC; Health Economics & Outcomes Research, IMS Health Asia Pacific, Singapore. Electronic address: sctan@sg.imshealth.com.
Wang X; ICU, First Affiliated Hospital of Medical College of Xi'an Jiao Tong University, Xi'an, China.
Wu B; Respiratory and Critical Care Centre, The 3(rd) Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Kang H; Department of Critical Care Medicine, Chinese PLA General Hospital, Beijing, China.
Li Q; Surgical Intensive Care Unit, Department of General Surgery, Jiangsu Province Hospital, Nanjing, China.
Chen Y; Outcomes Research, Pfizer Investment Co. Ltd., Beijing, China.
Chen CI; Outcomes Research, Pfizer Investment Co. Ltd., Beijing, China.
Hajek P; Outcomes Research, Pfizer Inc., Prague, Czech Republic.
Patel DA; HE&OR, Pharmerit International, Bethesda, MD, USA.
Gao X; HE&OR, Pharmerit International, Bethesda, MD, USA.

Value Health Reg Issues ; 3: 94-100, 2014 May.

Article em En | MEDLINE | ID: mdl-29702944

Palavras-chave

cost-effectiveness; linezolid; methicillin-resistant Staphylococcus aureus; nosocomial pneumonia; vancomycin

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_financiamento_saude Tipo de estudo: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Value Health Reg Issues Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google